Fendermal 25 μg/h, 50 μg/h, 75 μg/h, 100 μg/h Transdermal patches
PDF Leaflet Revision Date: 10 June 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Management of chronic intractable pain requiring opioid analgesia.
Dosage (summary)
Initial dose for opioid-nau00efve adults: 25 u03bcg/h; titrate based on response.
Onset of Action / Duration
Onset: 12-24 hours, Duration: 72 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding during treatment and for 72 hours after removal.
Key Drug Interactions
- CYP3A4 inhibitors
- CNS depressants
- MAO inhibitors
Contraindications
- Hypersensitivity to fentanyl
- Acute or postoperative pain
- Respiratory depression
- Bradycardia
- Children under 12 years
Common side effects
- Nausea
- Constipation
- Dizziness
- Somnolence
- Respiratory depression
Counselling Points
- Avoid alcohol and CNS depressants
- Keep out of reach of children
- Monitor for signs of overdose
Serious warnings
- Risk of serious respiratory depression
- Potential for opioid use disorder
- Monitor for sedation and respiratory depression
Important Disclaimer
The Fendermal 25 μg/h, 50 μg/h, 75 μg/h, 100 μg/h Transdermal patches professional information leaflet below is the property of Sandoz Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
